Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CTNM 
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CTNM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $22.88
1 Year Target Price $22.88
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 45.18% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 281.82M USD | Price to earnings Ratio - | 1Y Target Price 22.88 |
Price to earnings Ratio - | 1Y Target Price 22.88 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 3.35 - 20.30 | Updated Date 08/29/2025 |
52 Weeks Range 3.35 - 20.30 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.07 |
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.28 | Actual -0.62 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.42% | Return on Equity (TTM) -29.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 112087044 | Price to Sales(TTM) 11.15 |
Enterprise Value 112087044 | Price to Sales(TTM) 11.15 | ||
Enterprise Value to Revenue 8.25 | Enterprise Value to EBITDA 20.76 | Shares Outstanding 21625200 | Shares Floating 14969324 |
Shares Outstanding 21625200 | Shares Floating 14969324 | ||
Percent Insiders 1.61 | Percent Institutions 73.94 |
Upturn AI SWOT
Contineum Therapeutics, Inc. Class A Common Stock
Company Overview
History and Background
Contineum Therapeutics, Inc. (CTNM) is a biopharmaceutical company focused on discovering and developing new therapies targeting the neurobiology of the brain to treat neurodegenerative diseases and their associated clinical manifestations. Founded in 2017, the company went public on April 5, 2024.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Development of novel small molecule therapeutics for neurodegenerative diseases such as multiple sclerosis and Parkinson's disease.
Leadership and Structure
The leadership team includes highly experienced executives in drug development. Details regarding organizational structure are available from the company's public filings.
Top Products and Market Share
Key Offerings
- PIPE-791: A selective LPA1 receptor antagonist being developed for multiple sclerosis. Currently in Phase 2 clinical trials. Competitors include existing MS treatments from Biogen (BIIB) and Novartis (NVS), as well as emerging therapies.
- PIPE-307: A selective M1 receptor positive allosteric modulator being developed for Parkinson's disease dementia. Currently in Phase 1 clinical trials. Competitors include treatments for Parkinson's symptoms and dementia from companies like AbbVie (ABBV) and Acadia Pharmaceuticals (ACAD).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. The neurodegenerative disease therapeutics market is growing due to the aging population and increasing prevalence of these diseases.
Positioning
Contineum Therapeutics is positioned as an innovator in developing novel small molecule therapies targeting specific pathways in neurodegenerative diseases. Their competitive advantage lies in their differentiated approach and potential for improved efficacy and safety compared to existing treatments.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease therapies is substantial, estimated to be tens of billions of dollars annually. Contineum Therapeutics is positioned to capture a portion of this market with successful development and commercialization of their pipeline.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Experienced management team
- Strong intellectual property portfolio
- Pipeline with multiple clinical-stage programs
Weaknesses
- Early stage of development
- High cash burn rate
- Dependence on clinical trial success
- Limited commercialization experience
Opportunities
- Partnerships and collaborations
- Expansion of pipeline into new indications
- Accelerated regulatory pathways
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Novartis (NVS)
- AbbVie (ABBV)
- Acadia Pharmaceuticals (ACAD)
Competitive Landscape
Contineum Therapeutics is a smaller player competing with large, established pharmaceutical companies. Their advantage lies in their novel therapeutic approaches, but they face significant challenges in terms of resources and experience.
Growth Trajectory and Initiatives
Historical Growth: N/A due to recent IPO
Future Projections: Future growth depends on successful clinical trials and potential partnerships. Analyst estimates are speculative at this early stage.
Recent Initiatives: Focus is on advancing PIPE-791 and PIPE-307 through clinical development.
Summary
Contineum Therapeutics is an early-stage biopharmaceutical company with a focus on neurodegenerative diseases. The company's pipeline and innovative therapeutic approaches are promising, but it faces significant risks associated with clinical development and competition. Successful clinical trial results and strategic partnerships are crucial for future growth and shareholder value. Its success will greatly depend on positive trial outcomes in the coming years.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Contineum Therapeutics, Inc. Class A Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-04-05 | President, CEO & Director Mr. Carmine N. Stengone MBA, MS | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.contineum-tx.com |
Full time employees 41 | Website https://www.contineum-tx.com | ||
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.